1 active not recruiting, 1 not yet recruiting, 1 recruiting. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Remibrutinib (Open Label): new trials by email Literature Review of Remibrutinib (Open Label) trials Research Report on Remibrutinib (Open Label)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS Remibrutinib (Open Label) - Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive | Phase 2 | Not yet recruiting | Moein Amin | 20 | 2027-03-01 | 2026-08-19 |
| A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis Remibrutinib (blinded), Placebo, Remibrutinib (Open label) - Secondary Progressive Multiple Sclerosis (SPMS) | Phase 3 | Recruiting | Novartis Pharmaceuticals | 1275 | 2025-11-11 | 2026-10-13 |
| A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis Remibrutinib (Blinded), Placebo, Remibrutinib (Open Label) - Generalized Myasthenia Gravis | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 180 | 2025-02-07 | 2026-09-28 |
Multiple Sclerosis (2) · Multiple Sclerosis, Chronic Progressive (2) · Multiple Sclerosis, Relapsing-Remitting (1) · Myasthenia Gravis (1) · Recurrence (1)
Novartis Pharmaceuticals (2) · Moein Amin (1)
United States (3) · Argentina (2) · Australia (2) · Brazil (2) · Canada (2) · China (2) · France (2) · Germany (2) · India (2) · Italy (2) · Netherlands (2) · Poland (2) · Romania (2) · Spain (2) · United Kingdom (2)
2023 (1), 2025 (1)